Transketolase-like protein 1 confers resistance to serum withdrawal in vitro
Standard
Transketolase-like protein 1 confers resistance to serum withdrawal in vitro. / Hartmannsberger, Diana; Mack, Brigitte; Eggert, Carola; Denzel, Sabine; Stepp, Herbert; Betz, Christian S; Gires, Olivier.
In: CANCER LETT, Vol. 300, No. 1, 01.01.2011, p. 20-9.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Transketolase-like protein 1 confers resistance to serum withdrawal in vitro
AU - Hartmannsberger, Diana
AU - Mack, Brigitte
AU - Eggert, Carola
AU - Denzel, Sabine
AU - Stepp, Herbert
AU - Betz, Christian S
AU - Gires, Olivier
N1 - Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Transketolase-like protein 1 (TKTL1) is a member of the family of transketolase enzymes of which the founder member transketolase (TKT) is known to play a central role in the non-oxidative part of the pentose phosphate pathway. According to several publications TKTL1 is the only family member, whose expression is substantially de-regulated in a variety of solid tumours. Over-expression of TKTL1 correlates with poor prognosis of cancer patients and TKTL1 itself represents a potential therapeutic target owing to its possible involvement in the regulation of the proliferation and metabolism of cancer cells. We show that exogenously expressed TKTL1 provides HEK293 cells with moderate growth advantages under standard culture conditions, while protecting cells from growth factor withdrawal-induced apoptosis. Importantly, we identified TKTL1 with the JFC12T10 antibody as a 65kDa protein, which was however absent in most tumour cell lines tested. Primary head and neck squamous cell carcinomas of various localisations were characterised by a focal pattern with single cells strongly expressing TKTL1, rather than by a homogeneous expression pattern within the tumour mass.
AB - Transketolase-like protein 1 (TKTL1) is a member of the family of transketolase enzymes of which the founder member transketolase (TKT) is known to play a central role in the non-oxidative part of the pentose phosphate pathway. According to several publications TKTL1 is the only family member, whose expression is substantially de-regulated in a variety of solid tumours. Over-expression of TKTL1 correlates with poor prognosis of cancer patients and TKTL1 itself represents a potential therapeutic target owing to its possible involvement in the regulation of the proliferation and metabolism of cancer cells. We show that exogenously expressed TKTL1 provides HEK293 cells with moderate growth advantages under standard culture conditions, while protecting cells from growth factor withdrawal-induced apoptosis. Importantly, we identified TKTL1 with the JFC12T10 antibody as a 65kDa protein, which was however absent in most tumour cell lines tested. Primary head and neck squamous cell carcinomas of various localisations were characterised by a focal pattern with single cells strongly expressing TKTL1, rather than by a homogeneous expression pattern within the tumour mass.
KW - Apoptosis
KW - Cell Line
KW - Cell Proliferation
KW - Humans
KW - Intercellular Signaling Peptides and Proteins
KW - Molecular Weight
KW - Pentose Phosphate Pathway
KW - RNA, Messenger
KW - RNA, Small Interfering
KW - Transketolase
KW - Journal Article
U2 - 10.1016/j.canlet.2010.08.017
DO - 10.1016/j.canlet.2010.08.017
M3 - SCORING: Journal article
C2 - 20884117
VL - 300
SP - 20
EP - 29
JO - CANCER LETT
JF - CANCER LETT
SN - 0304-3835
IS - 1
ER -
